FIELD: medicine.
SUBSTANCE: the present innovation deals with applying antibodies to kinase sgk3 for detecting the expression and /or the function of kinase sgk3 in eucaryotic cells to diagnose diseases associated with affected activity of ionic canals, especially sodium and/or potassium canals. It has bed demonstrated that kinase sgk3 stimulates the activity of epithelial sodium canal, and diagnostic detection of the disorders of its expression and/or function could be considered as the measure that enables to establish the reason of hypertonicity, epileptic attack and affected cardiac stimulation. It has been stated on that kinase sgk3-mediated activation of potassium canal is of anti-apoptosis action.
EFFECT: higher efficiency.
6 cl, 3 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| sgk1 AS DIAGNOSTIC AND THERAPEUTIC TARGET | 2003 |
|
RU2331072C2 |
| DRUGS CONTAINING HUMAN h-sgk KINASE INHIBITORS CONTROLLING CELL VOLUME | 2000 |
|
RU2288718C9 |
| QUANTITATIVE DIAGNOSTIC ANALYSIS OF HYPERTENSION | 2002 |
|
RU2287160C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS | 2006 |
|
RU2411242C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2383545C2 |
| N-(4-(AZAINDAZOL-6-IL)-PHENYL)-SULFONAMIDES AND THEIR USE AS DRUGS | 2014 |
|
RU2671864C2 |
| THERAPEUTIC DRUG FOR DISEASES RELATED TO ENDOPLASMIC RETICULUM CELL DEATH IN CORNEAL ENDOTHELIUM | 2014 |
|
RU2712967C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2387653C2 |
| METHOD OF USAGE OF (HALO BENZYLOXY)BENZYLAMINO-PROPANAMIDE FOR PRODUCTION OF MEDICATIONS WITH SELECTIVE MODULATING ACTIVITY ON SODIUM AND/OR CALCIUM CHANNELS | 2005 |
|
RU2391973C2 |
| METHODS FOR DETERMINING EFFICACY OF LIGANDS OF SODIUM/PROTON ANTIPORTERS | 2009 |
|
RU2519345C2 |
